慢性丙型肝炎患者胰岛素抵抗的发病机制及对抗病毒治疗的影响

刘大吉; 陈青锋

doi:10.3969/j.issn.1001-5256.2017.06.029

慢性丙型肝炎患者胰岛素抵抗的发病机制及对抗病毒治疗的影响

DOI: 10.3969/j.issn.1001-5256.2017.06.029

兰州大学第一医院

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2382
- HTML全文浏览量: 4
- PDF下载量: 447
- 被引次数: 0
出版历程
- 出版日期: 2017-06-20

Pathogenesis of insulin resistance and its impact on antiviral therapy in patients with chronic hepatitis C

摘要

摘要: 慢性HCV感染是肝纤维化、肝硬化及肝细胞癌的重要发病原因。胰岛素抵抗(IR)是HCV感染的重要病理学特征之一。IR可加速肝纤维化、肝脂肪变性、肝细胞癌的发病进程,而且影响抗病毒治疗的效果,因此,HCV相关性IR在HCV感染的任何阶段都可作为药物治疗的靶点。综述了丙型肝炎患者并发IR的发病机制,两者间的相互作用,以及IR对抗病毒治疗的影响。
- 肝炎,丙型,慢性 /
- 胰岛素抵抗 /
- 综述
Abstract: Chronic hepatitis C virus (HCV) infection is an important cause of hepatic fibrosis, liver cirrhosis, and hepatocellular carcinoma (HCC) . Insulin resistance (IR) is one of the important pathological features of HCV infection. IR can accelerate the development of hepatic fibrosis, hepatic steatosis, and HCC and affect the efficacy of antiviral therapy. Therefore, HCV-related IR can be the target of pharmacotherapy during any stage of HCV infection. This article reviews the pathogenesis of IR in patients with hepatitis C, the interaction between them, and the impact of IR on antiviral therapy.
- hepatitis C, chronic /
- insulin resistance /
- review

HTML全文

参考文献(31)

[1]SHI YQ, WANG X.Analysis the treatment of type 2 diabetes mellitus from the five internal organs[J].J Changchun Univ Chin Med, 2015, 31 (1) :68-70. (in Chinese) 史云秋, 王旭.从五脏论治2型糖尿病[J].长春中医药大学学报, 2015, 31 (1) :68-70.

[2]ASSELAH T, ESTRABAUD E, BIECHE I, et al.Hepatitis C:viral and host factors associated with non-response to pegylated interferon plus ribavirin[J].Liver Int, 2010, 30 (9) :1259-1269.

[3]KOSTERIN SA, BRATKOVA NF, KURSKII MD.Possible mechanism of the regulation of smooth muscle relaxation by calcium ions[J].Biofizika, 1987, 32 (2) :327-332.

[4]PERSICO M, IOLASCON A.Steatosis as a co-factor in chronic liver diseases[J].World J Gastroenterol, 2010, 16 (10) :1171-1176.

[5]MASARONE M, La MURA V, BRUNO S, et al.Steatohepatitis is associated with diabetes and fibrosis in genotype 1b HCV-related chronic liver disease[J].J Viral Hepatitis, 2007, 14 (10) :714-720.

[6]NEGRO F.Steatosis and insulin resistance in response to treatment of chronic hepatitis C[J].J Viral Hepatitis, 2012, 19 (Suppl 1) :42-47.

[7]BOCHUD PY, CAI T, OVERBECK K, et al.Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C[J].J Hepatol, 2009, 51 (4) :655-666.

[8]GARINIS GA, FRUCI B, MAZZA A, et al.Metformin versus dietary treatment in nonalcoholic hepatic steatosis:a randomized study[J].Int J Obesity, 2010, 34 (8) :1255-1264.

[9]ADINOLFI LE, RESTIVO L, MARRONE A.The predictive value of steatosis in hepatitis C virus infection[J].Expert Rev Gastroent, 2013, 7 (3) :205-213.

[10]SHEIKH MY, CHOI J, QADRI I, et al.Hepatitis C virus infection:molecular pathways to metabolic syndrome[J].Hepatology, 2008, 47 (6) :2127-2133.

[11]KONG WL, YANG YL, XU HQ, et al.Relationship between liver function and virological response in patients with chronic hepatic C during entiviral treatment[J].J JIlin Univ:Med Edit, 2016, 42 (1) :99-103. (in Chiese) 孔文丽, 杨以良, 徐洪芹, 等.慢性丙型肝炎患者抗病毒治疗中肝功能与病毒学应答的关系[J].吉林大学学报:医学版, 2016, 42 (1) :99-103.

[12]HAASTERT-TALINI K, GROTHE C.Comment to the paper:Acceleration of peripheral nerve regeneration using nerve conduits in combination with induced pluripotent stem cell technology and a basic fibroblast growth factor drug delivery system by M.Ikeda, T.Uemura, K.Takamatsu, M.Okada, K.Kazuki, Y.Tabata, Y.Ikada, H.Nakamura, J Biomed Mater Res A.2013 Jun 3 doi:10.1002/jbm.a.34816[J].J Biomed Mater Res A, 2014, 102 (4) :1219-1220.

[13]SARIN SK, KUMAR CK.Treatment of patients with genotype 3chronic hepatitis C-current and future therapies[J].Liver Int, 2012, 32 (Suppl 1) :141-145.

[14]ABENAVOLI L, MAZZA M, ALMASIO PL.The optimal dose of ribavirin for chronic hepatitis C:from literature evidence to clinical practice:the optimal dose of ribavirin for chronic hepatitis C[J].Hepat Mon, 2011, 11 (4) :240-246.

[15]SANYAL AJ.Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C[J].Liver Int, 2011, 31 (Suppl 1) :23-28.

[16]PERSICO M, CAPASSO M, PERSICO E, et al.Suppressor of cytokine signaling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis:insulin resistance and response to antiviral therapy[J].Hepatology, 2007, 46 (4) :1009-1015.

[17]SUN LJ, LI SC, ZHAO YH, et al.HCV core protein down-regulates AMP-activated protein kinase and the gucose metabolism disorders in hepatocytes[J].Chin Hepatol, 2013, 18 (3) :150-154. (in Chinese) 孙丽杰, 李树臣, 赵勇华, 等.丙型肝炎病毒核心蛋白下调AMP激活蛋白激酶对肝细胞脂类代谢的影响[J].肝脏, 2013, 18 (3) :150-154.

[18]PARVAIZ F, MANZOOR S, TARIQ H, et al.Hepatitis C virus infection:molecular pathways to insulin resistance[J].Virol J, 2011, 8:474.

[19]PARVAIZ F, MANZOOR S, IQBAL J, et al.Hepatitis C virus NS5A promotes insulin resistance through IRS-1 serine phosphorylation and increased gluconeogenesis[J].World J Gastroenterol, 2015, 21 (43) :12361-12369.

[20]CHEN JZ, WANG Q, XU S.Hepatitis C virus core protein upregulates the transcription of PCK1 through FOXO1/PGC-1αpathway[J].Acta Microbiol Sin, 2012, 52 (1) :52-59. (in Chinese) 陈继征, 王倩, 徐松.丙型肝炎病毒核心蛋白通过FOXO1/PGC-1α途径上调磷酸烯醇式丙酮酸羧基酶的转录[J].微生物学报, 2012, 52 (1) :52-59.

[21]YU JW, SUN LJ, LIU W, et al.Changes in Th17 cells and natural killer T cells in peripheral blood of chronic hepatitis C patients with insulin resistance[J].Chin Hepatol, 2012, 17 (5) :319-321. (in Chinese) 于建武, 孙丽杰, 刘伟, 等.Th17细胞和自然杀伤性T细胞在胰岛素抵抗的慢性丙型肝炎患者外周血中的变化[J].肝脏, 2012, 17 (5) :319-321.

[22]WANG HL, LI XH, WANG GQ, et al.Results of antiviral treatment of chronic hepatitis C cases complicated with insulin resistance[J].China Trop Med, 2013, 13 (3) :390, 392. (in Chinese) 王会琳, 李新华, 王国强, 等.慢性丙型肝炎合并胰岛素抵抗的抗病毒治疗临床观察[J].中国热带医学, 2013, 13 (3) :390, 392.

[23]WEI L, LIU JK.Influence of lipid metabolism on the antiviral response in patients with chronic hepatitis C[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2012, 6 (5) :447-450. (in Chinese) 魏莉, 刘江奎.脂类代谢对慢性丙型肝炎抗病毒治疗疗效的影响[J/CD].中华实验和临床感染病杂志:电子版, 2012, 6 (5) :447-450.

[24]YU JW, SUN LJ, ZHAO YH, et al.The effect of metformin on the efficacy of antiviral therapy in patients with genotype 1 chronic hepatitis C and insulin resistance[J].Int J Infect Dis, 2012, 16 (6) :e436-e441.

[25]PREMJI R, ROOPNARINESINGH N, QAZI N, et al.New-onset diabetes mellitus with exposure to ledipasvir and sofosbuvir[J].J Invest Med High Impact Case Rep, 2015, 3 (4) :2324709615623300.

[26]POL S, VALLET-PICHARD A, COROUGE M.Treatment of hepatitis C virus genotype 3-infection[J].Liver Int, 2014, 34 (Suppl1) :18-23.

[27]LAWITZ E, MANGIA A, WYLES D, et al.Sofosbuvir for previously untreated chronic hepatitis C infection[J].New Engl J Med, 2013, 368 (20) :1878-1887.

[28]FLAMM SL.Commentary:sofosbuvir for treatment of hepatitis C virus genotype 2 or 3 infection in patients without treatment options[J].Gastroenterol Hepatol, 2013, 9 (10) :682-683.

[29]GRASSO A, MALFATTI F, TESTA R.Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C?[J].World J Gastroenterol, 2013, 19 (41) :6947-6956.

[30]KIRAN Z, ZUBERI BF, ANIS D, et al.Insulin resistance in non-diabetic patients of chronic Hepatitis C[J].Pak J Med Sci, 2013, 29 (1) :201-204.

[31]BOSE SK, RAY R.Hepatitis C virus infection and insulin resistance[J].World J Diabetes, 2014, 5 (1) :52-58.

施引文献

资源附件(0)

访问统计